The three musketeers: uniting against CLL

Marwan Kwok; Tatjana Stankovic

doi:10.1182/blood.2021014826

The three musketeers: uniting against CLL

Marwan Kwok, Tatjana Stankovic

Cancer and Genomic Sciences

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

In this issue of Blood, Huber et al¹ present results of an important prospective clinical trial, demonstrating that the combination of obinutuzumab, ibrutinib, and venetoclax produces high rates of undetectable measurable residual disease and remarkable 2-year progression-free survival in previously untreated del(17p) or TP53-mutated chronic lymphocytic leukemia (CLL).

Original language	English
Pages (from-to)	1264-1265
Number of pages	2
Journal	Blood
Volume	139
Issue number	9
DOIs	https://doi.org/10.1182/blood.2021014826
Publication status	Published - 3 Mar 2022

Keywords

triple therapy for CLL

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1182/blood.2021014826

Cite this

@article{c2d4d555464843828dfcb4c8247a1b42,

title = "The three musketeers: uniting against CLL",

abstract = "In this issue of Blood, Huber et al1 present results of an important prospective clinical trial, demonstrating that the combination of obinutuzumab, ibrutinib, and venetoclax produces high rates of undetectable measurable residual disease and remarkable 2-year progression-free survival in previously untreated del(17p) or TP53-mutated chronic lymphocytic leukemia (CLL). ",

keywords = "triple therapy for CLL",

author = "Marwan Kwok and Tatjana Stankovic",

year = "2022",

month = mar,

day = "3",

doi = "10.1182/blood.2021014826",

language = "English",

volume = "139",

pages = "1264--1265",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "9",

}

TY - JOUR

T1 - The three musketeers

T2 - uniting against CLL

AU - Kwok, Marwan

AU - Stankovic, Tatjana

PY - 2022/3/3

Y1 - 2022/3/3

N2 - In this issue of Blood, Huber et al1 present results of an important prospective clinical trial, demonstrating that the combination of obinutuzumab, ibrutinib, and venetoclax produces high rates of undetectable measurable residual disease and remarkable 2-year progression-free survival in previously untreated del(17p) or TP53-mutated chronic lymphocytic leukemia (CLL).

AB - In this issue of Blood, Huber et al1 present results of an important prospective clinical trial, demonstrating that the combination of obinutuzumab, ibrutinib, and venetoclax produces high rates of undetectable measurable residual disease and remarkable 2-year progression-free survival in previously untreated del(17p) or TP53-mutated chronic lymphocytic leukemia (CLL).

KW - triple therapy for CLL

U2 - 10.1182/blood.2021014826

DO - 10.1182/blood.2021014826

M3 - Comment/debate

SN - 0006-4971

VL - 139

SP - 1264

EP - 1265

JO - Blood

JF - Blood

IS - 9

ER -

The three musketeers: uniting against CLL

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this